ImpediMed Ltd
ASX:IPD

Watchlist Manager
ImpediMed Ltd Logo
ImpediMed Ltd
ASX:IPD
Watchlist
Price: 0.055 AUD 1.85% Market Closed
Market Cap: 111.3m AUD
Have any thoughts about
ImpediMed Ltd?
Write Note

Intrinsic Value

The intrinsic value of one IPD stock under the Base Case scenario is 0.079 AUD. Compared to the current market price of 0.055 AUD, ImpediMed Ltd is Undervalued by 30%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

IPD Intrinsic Value
0.079 AUD
Undervaluation 30%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
ImpediMed Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for IPD cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about IPD?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
ImpediMed Ltd

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about ImpediMed Ltd

Provide an overview of the primary business activities
of ImpediMed Ltd.

What unique competitive advantages
does ImpediMed Ltd hold over its rivals?

What risks and challenges
does ImpediMed Ltd face in the near future?

Has there been any significant insider trading activity
in ImpediMed Ltd recently?

Summarize the latest earnings call
of ImpediMed Ltd.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for ImpediMed Ltd.

Provide P/S
for ImpediMed Ltd.

Provide P/E
for ImpediMed Ltd.

Provide P/OCF
for ImpediMed Ltd.

Provide P/FCFE
for ImpediMed Ltd.

Provide P/B
for ImpediMed Ltd.

Provide EV/S
for ImpediMed Ltd.

Provide EV/GP
for ImpediMed Ltd.

Provide EV/EBITDA
for ImpediMed Ltd.

Provide EV/EBIT
for ImpediMed Ltd.

Provide EV/OCF
for ImpediMed Ltd.

Provide EV/FCFF
for ImpediMed Ltd.

Provide EV/IC
for ImpediMed Ltd.

Show me price targets
for ImpediMed Ltd made by professional analysts.

What are the Revenue projections
for ImpediMed Ltd?

How accurate were the past Revenue estimates
for ImpediMed Ltd?

What are the Net Income projections
for ImpediMed Ltd?

How accurate were the past Net Income estimates
for ImpediMed Ltd?

What are the EPS projections
for ImpediMed Ltd?

How accurate were the past EPS estimates
for ImpediMed Ltd?

What are the EBIT projections
for ImpediMed Ltd?

How accurate were the past EBIT estimates
for ImpediMed Ltd?

Compare the revenue forecasts
for ImpediMed Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of ImpediMed Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of ImpediMed Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of ImpediMed Ltd compared to its peers.

Compare the P/E ratios
of ImpediMed Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing ImpediMed Ltd with its peers.

Analyze the financial leverage
of ImpediMed Ltd compared to its main competitors.

Show all profitability ratios
for ImpediMed Ltd.

Provide ROE
for ImpediMed Ltd.

Provide ROA
for ImpediMed Ltd.

Provide ROIC
for ImpediMed Ltd.

Provide ROCE
for ImpediMed Ltd.

Provide Gross Margin
for ImpediMed Ltd.

Provide Operating Margin
for ImpediMed Ltd.

Provide Net Margin
for ImpediMed Ltd.

Provide FCF Margin
for ImpediMed Ltd.

Show all solvency ratios
for ImpediMed Ltd.

Provide D/E Ratio
for ImpediMed Ltd.

Provide D/A Ratio
for ImpediMed Ltd.

Provide Interest Coverage Ratio
for ImpediMed Ltd.

Provide Altman Z-Score Ratio
for ImpediMed Ltd.

Provide Quick Ratio
for ImpediMed Ltd.

Provide Current Ratio
for ImpediMed Ltd.

Provide Cash Ratio
for ImpediMed Ltd.

What is the historical Revenue growth
over the last 5 years for ImpediMed Ltd?

What is the historical Net Income growth
over the last 5 years for ImpediMed Ltd?

What is the current Free Cash Flow
of ImpediMed Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for ImpediMed Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
ImpediMed Ltd

Current Assets 29.5m
Cash & Short-Term Investments 24.6m
Receivables 3.2m
Other Current Assets 1.6m
Non-Current Assets 17.5m
Long-Term Investments 54k
PP&E 1.4m
Intangibles 16m
Current Liabilities 4.7m
Accounts Payable 1.6m
Accrued Liabilities 1.2m
Other Current Liabilities 1.9m
Non-Current Liabilities 1.6m
Long-Term Debt 810k
Other Non-Current Liabilities 776k
Efficiency

Earnings Waterfall
ImpediMed Ltd

Revenue
10.3m AUD
Cost of Revenue
-1.3m AUD
Gross Profit
9m AUD
Operating Expenses
-30.2m AUD
Operating Income
-21.2m AUD
Other Expenses
1.4m AUD
Net Income
-19.8m AUD

Free Cash Flow Analysis
ImpediMed Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

IPD Profitability Score
Profitability Due Diligence

ImpediMed Ltd's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional Revenue Growth Forecast
ROE is Increasing
ROIC is Increasing
31/100
Profitability
Score

ImpediMed Ltd's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

IPD Solvency Score
Solvency Due Diligence

ImpediMed Ltd's solvency score is 82/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Negative Net Debt
Low D/E
82/100
Solvency
Score

ImpediMed Ltd's solvency score is 82/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

IPD Price Targets Summary
ImpediMed Ltd

Wall Street analysts forecast IPD stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IPD is 0.148 AUD with a low forecast of 0.091 AUD and a high forecast of 0.2 AUD.

Lowest
Price Target
0.091 AUD
65% Upside
Average
Price Target
0.148 AUD
169% Upside
Highest
Price Target
0.2 AUD
263% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for IPD?

Click here to dive deeper.

Dividends

ImpediMed Ltd
does not pay dividends
Shareholder Yield

Current shareholder yield for IPD is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

IPD Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

ImpediMed Ltd Logo
ImpediMed Ltd

Country

Australia

Industry

Health Care

Market Cap

111.3m AUD

Dividend Yield

0%

Description

ImpediMed Ltd. engages in the development and distribution of bioimpedance devices with a focus on medical applications in the fluid status area. The company is headquartered in Brisbane, Queensland and currently employs 73 full-time employees. The company went IPO on 2007-10-24. The firm develops various medical products that use bioimpedance spectroscopy (BIS) to measure and monitor fluid status and tissue composition. Its product includes SOZO Digital Health Platform. The company is a non-invasive BIS device delivers a snapshot of fluid status and tissue composition in approximately 30 seconds. The Company’s SOZO Applications offer clinicians deeper insights into a patient’s health. SOZO Applications include various software applications, such as L-Dex Analysis for Lymphedema, Body Composition Analysis, Segmental Analysis and HF-Dex Analysis for Heart Failure. The Company’s research devices include SFB7 and ImpediVET. SFB7 single channel, tetrapolar BIS device, which measures fluid status and tissue composition for clinical and research applications.

Contact

QUEENSLAND
Brisbane
Pinkenba, U 1 50 Parker Ct
+61738603700.0
www.impedimed.com

IPO

2007-10-24

Employees

73

Officers

MD, CEO & Director
Dr. Parmjot Bains M.D.
CFO & Executive Director
Mr. McGregor Grant BEc, C.A., FCIS, GAICD
Executive Director and VP of Product Development & Customer Solutions
Mr. Andrew Grant B.E., M.B.A.
Senior Vice President of R&D and Technology
Mr. Dennis Schlaht
Senior Vice President of Sales & Customer Success
Mr. Tim Benkovic
Director of Human Resources
Ashley Munoz
Show More
Chief Medical Center
Dr. Steven Chen M.B.A., M.D.
Company Secretary
Ms. Leanne Ralph AAICD, ACIS, BBus
Medical Director
Dr. Walton A. Taylor
Show Less

See Also

Discover More
What is the Intrinsic Value of one IPD stock?

The intrinsic value of one IPD stock under the Base Case scenario is 0.079 AUD.

Is IPD stock undervalued or overvalued?

Compared to the current market price of 0.055 AUD, ImpediMed Ltd is Undervalued by 30%.

Back to Top